Pimicotinib

DRUG3 trials

Sponsors

Abbisko Therapeutics Co, Ltd, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Second Affiliated Hospital, School of Medicine, Zhejiang University

Conditions

PharmacokineticsTenosynovial Giant Cell TumorTenosynovial Giant Cell Tumor, Diffuse

Phase 1

The Study to Assess the Pharmacokinetics of Pimicotinib in Subjects With Mild and Moderate Hepatic Impairment Relative to Subjects With Normal Hepatic Function

CompletedNCT06562946

Abbisko Therapeutics Co, LtdPharmacokinetics

Start: 2024-09-20End: 2025-01-10Updated: 2025-01-20

Phase 2

Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)

RecruitingNCT07499362

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyTenosynovial Giant Cell Tumor

Start: 2026-03-26End: 2029-11-22Target: 20Updated: 2026-09-10

Neoadjuvant Pimicotinib Combined With Surgery Versus Upfront Surgery for Diffuse Tenosynovial Giant Cell Tumor

Not yet recruitingNCT07707882

Second Affiliated Hospital, School of Medicine, Zhejiang UniversityTenosynovial Giant Cell Tumor, Diffuse

Start: 2027-10-01End: 2030-09-30Target: 84Updated: 2026-07-16